Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VR-based Attentional Bias as a Biomarker for Tobacco Use Disorder
NCT06582888Phase 1Recruiting
- Sponsor
- University of California, San Diego
- Start
- Nov 2024
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Tobacco Use Disorder (TUD) comparing Varenicline with Placebo (2 arms). Primary endpoints: Change in Virtual Reality Attentional Bias at 8 days, Nicotine craving at 8 days and 3 more. Started Nov 2024; status: recruiting.
02
Drugs
varenicline
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT06582888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06582888.